Weekly GLP-1 receptor agonist (Trulicity) for type 2 diabetes.
Typical dose range: 0.75–4.5 mg
Frequency: Weekly
Route: Subcutaneous
Half-life: ~5 days
Evidence level: Strong (FDA-approved)
Slightly less weight-loss potency than semaglutide but a clean diabetes profile and proven CV outcome data.